Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

698.49 +3.50 (+0.50%)

Streaming Delayed Price Updated: 12:45 PM EST, Nov 14, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	391,644
Open	697.19
Bid (Size)	697.49 (40)
Ask (Size)	698.63 (40)
Prev. Close	694.99
Today's Range	685.95 - 699.27
52wk Range	476.49 - 823.56
Shares Outstanding	91,779,465
Dividend Yield	0.25%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

What's going on in today's session: S&P500 movers ↗

November 13, 2025

Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.

Via Chartmill

Tech Sector Tremors: Is the AI Bubble Deflating, and What's Next for the Market?

November 13, 2025

As of mid-November 2025, a palpable unease has settled over the technology sector, long the darling of investors and the primary engine of market growth. After a period of unprecedented outperformance,...

Via MarketMinute

Performance

YTD	-2.3%	-2.3%
1 Month	+22.0%	+22.0%
3 Month	+23.4%	+23.4%
6 Month	+19.4%	+19.4%
1 Year	-13.2%	-13.2%

More News

Wall Street Falls On US Government Reopening Day, Bitcoin Slides To $100,000: What's Moving Markets Thursday? ↗

November 13, 2025

Via Benzinga

Explore the top gainers and losers within the S&P500 index in today's session. ↗

November 13, 2025

Via Chartmill

Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs

November 13, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Here Are the Top Growth Healthcare Stocks Every New Investor Should Know ↗

November 13, 2025

Via The Motley Fool

CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial ↗

November 11, 2025

Via Benzinga

Incyte (NASDAQ:INCY) Q3 Earnings: Leading The Immuno-Oncology Pack

November 10, 2025

Via StockStory

Winners And Losers Of Q3: Regeneron (NASDAQ:REGN) Vs The Rest Of The Immuno-Oncology Stocks

November 10, 2025

Via StockStory

Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60% ↗

November 08, 2025

Via Investor's Business Daily

Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet

November 08, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review

November 07, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years ↗

November 06, 2025

Via Benzinga

Looking Into Regeneron Pharmaceuticals Inc's Recent Short Interest ↗

November 04, 2025

Via Benzinga

The Shadow of Doubt: Why Investors Are 'Taking Fright' as Markets Brace for Reality

November 04, 2025

Via MarketMinute

5 Revealing Analyst Questions From Regeneron’s Q3 Earnings Call

November 04, 2025

Via StockStory

Michael Burry Is Super-Bearish On Palantir — With 5 Million Puts ↗

November 03, 2025

Via Benzinga

Regeneron Announces Investor Conference Presentations

November 03, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

2 Beaten-Down Stocks That Could Be About to Rally ↗

November 03, 2025

Via The Motley Fool

Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award

October 31, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

REGN Q3 Deep Dive: Pipeline, Regulatory Progress, and Label Expansion Take Center Stage

October 29, 2025

Via StockStory

Regeneron (REGN) Q3 2025 Earnings Call Transcript ↗

October 28, 2025

Via The Motley Fool

Uncover the latest developments among S&P500 stocks in today's session. ↗

October 28, 2025

Via Chartmill

Explore the top gainers and losers within the S&P500 index in today's session. ↗

October 28, 2025

Via Chartmill

Nasdaq 100 Hits 26,000, Gold Falls Below $4,000: What's Moving Markets Tuesday? ↗

October 28, 2025

Via Benzinga

Frequently Asked Questions

Is Regeneron Pharmaceuticals publicly traded?

Yes, Regeneron Pharmaceuticals is publicly traded.

What exchange does Regeneron Pharmaceuticals trade on?

Regeneron Pharmaceuticals trades on the Nasdaq Stock Market

What is the ticker symbol for Regeneron Pharmaceuticals?

The ticker symbol for Regeneron Pharmaceuticals is REGN on the Nasdaq Stock Market

What is the current price of Regeneron Pharmaceuticals?

The current price of Regeneron Pharmaceuticals is 698.49

When was Regeneron Pharmaceuticals last traded?

The last trade of Regeneron Pharmaceuticals was at 11/14/25 12:45 PM ET

What is the market capitalization of Regeneron Pharmaceuticals?

The market capitalization of Regeneron Pharmaceuticals is 64.11B

How many shares of Regeneron Pharmaceuticals are outstanding?

Regeneron Pharmaceuticals has 64B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Regeneron Pharmaceuticals (NQ:REGN)

Price and Volume

Top News

Performance

More News

Frequently Asked Questions

Starting at $3.75/week.

Subscribe Today